Veracyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
February 22, 2024 at 04:12 pm EST
Share
Veracyte, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 18.92 million compared to USD 33.36 million a year ago. Revenue was USD 361.05 million compared to USD 296.54 million a year ago.
Net loss was USD 74.4 million compared to USD 36.56 million a year ago. Basic loss per share from continuing operations was USD 1.02 compared to USD 0.51 a year ago.
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.